Genprex, Inc. Files 8-K on Dec 23, 2025
Ticker: GNPX · Form: 8-K · Filed: Dec 23, 2025 · CIK: 1595248
Sentiment: neutral
Topics: corporate-filing, 8-k, pharmaceuticals
Related Tickers: GNPX
TL;DR
Genprex (GNPX) filed its 8-K on 12/23/25, updating corporate info. Nothing major, just housekeeping.
AI Summary
Genprex, Inc. filed an 8-K on December 23, 2025, reporting on other events and financial statements. The filing details the company's corporate structure, including its state of incorporation (Delaware) and fiscal year end (December 31). Genprex, Inc. is a pharmaceutical preparations company based in Austin, Texas.
Why It Matters
This filing provides an official update on Genprex, Inc.'s corporate and financial reporting status, which is crucial for investors and stakeholders to track the company's compliance and operational details.
Risk Assessment
Risk Level: low — This filing is a routine corporate disclosure and does not appear to contain significant new financial or operational information that would immediately impact risk.
Key Numbers
- 1231 — Fiscal Year End (Indicates the end of the company's financial reporting year.)
- 001-38244 — SEC File Number (Unique identifier for Genprex, Inc.'s filings with the SEC.)
Key Players & Entities
- Genprex, Inc. (company) — Registrant
- 0001595248 (company) — Central Index Key
- 2834 (company) — Standard Industrial Classification (Pharmaceutical Preparations)
- TX (company) — State of Incorporation
- 1231 (company) — Fiscal Year End
- 001-38244 (company) — SEC File Number
- 251594696 (company) — Film Number
- Austin, TX (company) — Business Address City/State
- 512-537-7997 (company) — Business Phone
- December 23, 2025 (date) — Date of report
FAQ
What is the primary business of Genprex, Inc.?
Genprex, Inc. is in the Pharmaceutical Preparations industry, as indicated by its SIC code 2834.
When was this Form 8-K filed?
This Form 8-K was filed on December 23, 2025.
Where is Genprex, Inc. headquartered?
Genprex, Inc.'s principal executive offices are located in Austin, TX.
What is Genprex, Inc.'s fiscal year end?
Genprex, Inc.'s fiscal year ends on December 31.
What is the company's state of incorporation?
Genprex, Inc. is incorporated in Delaware.
Filing Stats: 1,051 words · 4 min read · ~4 pages · Grade level 15.9 · Accepted 2025-12-23 07:15:48
Key Financial Figures
- $0.001 — h registered Common Stock , par value $0.001 per share GNPX The Nasdaq Capital Ma
Filing Documents
- gnpx20251216_8k.htm (8-K) — 32KB
- 0001437749-25-038601.txt ( ) — 160KB
- gnpx-20251223.xsd (EX-101.SCH) — 3KB
- gnpx-20251223_def.xml (EX-101.DEF) — 11KB
- gnpx-20251223_lab.xml (EX-101.LAB) — 15KB
- gnpx-20251223_pre.xml (EX-101.PRE) — 11KB
- gnpx20251216_8k_htm.xml (XML) — 3KB
01 Other Items
Item 8.01 Other Items . As previously disclosed, on August 19, 2025, Genprex, Inc. (the "Company") received a letter from the Listing Qualifications Staff (the "Staff") of the Nasdaq Stock Market LLC ("Nasdaq") indicating that the Company was not in compliance with the minimum stockholders' equity requirement for the continued listing of the Company's common stock (the "Common Stock") on the Nasdaq Capital Market, under Listing Rule 5550(b)(1) (the "Stockholders' Equity Requirement"). Also as previously disclosed, the Nasdaq Hearings Panel (the "Panel") of Nasdaq notified the Company on November 25, 2025, that the Panel had approved the Company's request for an exception until December 31, 2025, to demonstrate long-term compliance with the Stockholders' Equity Requirement. As a result of proceeds raised from the Company's previously disclosed registered direct offerings which closed on October 24, 2025 and October 29, 2025, proceeds raised from the Company's usage of its "at the market" offering with H.C. Wainwright & Co., and the Company's usage of its equity line of credit with Lincoln Park Capital, LLC, as of the date of this Current Report on Form 8-K, the Company believes it has stockholders' equity in excess of the Stockholders' Equity Requirement. However, the Panel has not yet determined whether the Company has regained compliance with the Stockholders' Equity Requirement, and until the Panel determines that the Company is compliant with all applicable listing standards, there can be no assurance that the Common Stock will remain listed on the Nasdaq Capital Market. Cautionary Language Concerning Forward-Looking Statements This Current Report on Form 8-K contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company's ability to regain (as applicable)
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GENPREX, INC. Date: December 23, 2025 By: /s/ Ryan Confer Ryan Confer President, Chief Executive Officer and Chief Financial Officer (Principal Executive Officer and Principal Financial and Accounting Officer)